# Dapagliflozin and Cholesterol Metabolism in Type 2 Diabetes (DM2)

> **NCT03074630** · PHASE4 · COMPLETED · sponsor: **Amsterdam UMC, location VUmc** · enrollment: 12 (actual)

## Conditions studied

- Diabetes Mellitus, Type 2
- Hypercholesterolemia

## Interventions

- **DRUG:** Dapagliflozin
- **DRUG:** Rosuvastatin

## Key facts

- **NCT ID:** NCT03074630
- **Lead sponsor:** Amsterdam UMC, location VUmc
- **Sponsor class:** OTHER
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2016-05
- **Primary completion:** 2018-04
- **Final completion:** 2018-04
- **Target enrollment:** 12 (ACTUAL)
- **Last updated:** 2020-08-04

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03074630

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03074630, "Dapagliflozin and Cholesterol Metabolism in Type 2 Diabetes (DM2)". Retrieved via AI Analytics 2026-06-08 from https://api.ai-analytics.org/clinical/NCT03074630. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*